XML 46 R31.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment Data (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2022
Segment Reporting [Abstract] |
Revenue from External Customers by Geographic Areas | Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.
(Millions of dollars) | 2022 |  | 2021 |  | 2020
| United States |  | International |  | Total |  | United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions (a) | $ | 2,483 |  |  | $ | 1,825 |  |  | $ | 4,308 |  |  | $ | 2,253 |  |  | $ | 1,848 |  |  | $ | 4,101 |  |  | $ | 1,979 |  |  | $ | 1,617 |  |  | $ | 3,596 |
Medication Management Solutions | 1,935 |  |  | 598 |  |  | 2,533 |  |  | 1,863 |  |  | 570 |  |  | 2,432 |  |  | 1,865 |  |  | 589 |  |  | 2,454 |
Pharmaceutical Systems (a) | 533 |  |  | 1,468 |  |  | 2,001 |  |  | 428 |  |  | 1,400 |  |  | 1,828 |  |  | 404 |  |  | 1,183 |  |  | 1,587 |
Total segment revenues | $ | 4,950 |  |  | $ | 3,891 |  |  | $ | 8,841 |  |  | $ | 4,544 |  |  | $ | 3,817 |  |  | $ | 8,361 |  |  | $ | 4,247 |  |  | $ | 3,389 |  |  | $ | 7,637 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 2,190 |  |  | $ | 1,995 |  |  | $ | 4,185 |  |  | $ | 2,477 |  |  | $ | 2,748 |  |  | $ | 5,225 |  |  | $ | 1,872 |  |  | $ | 1,659 |  |  | $ | 3,532 |
Biosciences | 542 |  |  | 838 |  |  | 1,379 |  |  | 503 |  |  | 802 |  |  | 1,305 |  |  | 465 |  |  | 678 |  |  | 1,143 |
Total segment revenues | $ | 2,732 |  |  | $ | 2,833 |  |  | $ | 5,564 |  |  | $ | 2,980 |  |  | $ | 3,550 |  |  | $ | 6,530 |  |  | $ | 2,337 |  |  | $ | 2,337 |  |  | $ | 4,675 |
Interventional |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 1,094 |  |  | $ | 306 |  |  | $ | 1,400 |  |  | $ | 1,023 |  |  | $ | 274 |  |  | $ | 1,296 |  |  | $ | 891 |  |  | $ | 230 |  |  | $ | 1,121 |
Peripheral Intervention | 960 |  |  | 799 |  |  | 1,759 |  |  | 931 |  |  | 780 |  |  | 1,711 |  |  | 871 |  |  | 640 |  |  | 1,511 |
Urology and Critical Care | 986 |  |  | 319 |  |  | 1,305 |  |  | 894 |  |  | 338 |  |  | 1,232 |  |  | 815 |  |  | 315 |  |  | 1,130 |
Total segment revenues | $ | 3,040 |  |  | $ | 1,424 |  |  | $ | 4,464 |  |  | $ | 2,847 |  |  | $ | 1,392 |  |  | $ | 4,239 |  |  | $ | 2,577 |  |  | $ | 1,186 |  |  | $ | 3,762 |
Total Company revenues from continuing operations | $ | 10,722 |  |  | $ | 8,148 |  |  | $ | 18,870 |  |  | $ | 10,371 |  |  | $ | 8,760 |  |  | $ | 19,131 |  |  | $ | 9,161 |  |  | $ | 6,912 |  |  | $ | 16,074 |
(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.
Financial Information for Company's Segments | The following tables provide a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes and segment information for both capital expenditures and depreciation and amortization. Certain prior-period amounts have been recast to reflect the spin-off of the Diabetes Care business in fiscal year 2022, as noted above.
(Millions of dollars) | 2022 |  | 2021 |  | 2020
Income from Continuing Operations Before Income Taxes |  |  |  |  |
Medical (a) (b) | $ | 2,215 |  |  | $ | 1,985 |  |  | $ | 1,675 |
Life Sciences (c) | 1,710 |  |  | 2,391 |  |  | 1,405 |
Interventional | 1,081 |  |  | 933 |  |  | 724 |
Total Segment Operating Income | 5,006 |  |  | 5,311 |  |  | 3,806 |
Acquisition-related integration and restructuring expense | (173) |  |  | (179) |  |  | (299) |
Net interest expense | (382) |  |  | (460) |  |  | (521) |
Other unallocated items (d) | (2,668) |  |  | (2,981) |  |  | (2,573) |
Total Income from Continuing Operations Before Income Taxes | $ | 1,783 |  |  | $ | 1,692 |  |  | $ | 414 |
Capital Expenditures |  |  |  |  |
Medical | $ | 602 |  |  | $ | 740 |  |  | $ | 435 |
Life Sciences | 213 |  |  | 297 |  |  | 192 |
Interventional | 130 |  |  | 125 |  |  | 119 |
Corporate and All Other | 28 |  |  | 32 |  |  | 22 |
Total Capital Expenditures | $ | 973 |  |  | $ | 1,194 |  |  | $ | 769 |
Depreciation and Amortization |  |  |  |  |
Medical | $ | 1,144 |  |  | $ | 1,097 |  |  | $ | 1,064 |
Life Sciences | 283 |  |  | 352 |  |  | 286 |
Interventional | 789 |  |  | 769 |  |  | 750 |
Corporate and All Other | 13 |  |  | 12 |  |  | 14 |
Total Depreciation and Amortization | $ | 2,229 |  |  | $ | 2,230 |  |  | $ | 2,115 |
(a)The amounts in 2022, 2021 and 2020 include charges of $72 million $56 million and $244 million, respectively, recorded to Cost of products sold, related to the estimate of costs associated with remediation efforts for BD Alaris TM infusion pumps in the Medication Management Solutions unit. (b)The amount in 2022 includes a charge of $54 million to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit. The amount in 2020 included $41 million of charges to write down the value of fixed assets primarily in the Medication Delivery Solutions and Pharmaceutical Systems units. These charges were recorded to Cost of products sold. (c)The amount in 2020 included charges of $57 million recorded to Cost of products sold to write down the carrying value of certain intangible and other assets in the Biosciences and Integrated Diagnostic Solutions units. (d)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amounts in 2022, 2021 and 2020 also include pre-tax charges of $21 million, $361 million and $378 million, recorded to Other operating expense (income), net respectively, related to certain product liability matters, which is further discussed in Note 6.
Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment | Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location. The table below shows revenues from continuing operations and long-lived assets of continuing operations by geographic area:
(Millions of dollars) | 2022 |  | 2021 |  | 2020
Revenues |  |  |  |  |
United States | $ | 10,722 |  |  | $ | 10,371 |  |  | $ | 9,161 |
EMEA | 4,043 |  |  | 4,548 |  |  | 3,734 |
Greater Asia | 3,047 |  |  | 3,069 |  |  | 2,384 |
Other | 1,058 |  |  | 1,142 |  |  | 794 |
| $ | 18,870 |  |  | $ | 19,131 |  |  | $ | 16,074 |
Long-Lived Assets |  |  |  |  |
United States | $ | 36,617 |  |  | $ | 35,896 |  |  | $ | 36,317 |
EMEA | 5,126 |  |  | 5,778 |  |  | 5,660 |
Greater Asia | 1,528 |  |  | 1,607 |  |  | 1,466 |
Other | 1,079 |  |  | 860 |  |  | 753 |
Corporate | 442 |  |  | 465 |  |  | 411 |
| $ | 44,792 |  |  | $ | 44,606 |  |  | $ | 44,606 |

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration